Platinum Industries Limited has informed the Exchange regarding ''Disclosure on modified opinion in Financial results for quarter and nine months ended on 31 December 2025'.
PLATIND · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 6.3 pts more than Nifty Microcap 250 and 6.5 pts more than its Specialty Chemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Platinum Industries' board approved unaudited consolidated and standalone results for Q3 and 9M ended Dec 31, 2025, with auditors issuing a qualified (modified) opinion. The qualification stems from a July 7, 2025 fire at subsidiary M/s Platinum Polymers and Additives in Palghar, which damaged plant and inventory; the firm booked an insurance claim receivable of Rs 98.19 million and a net exceptional loss of Rs 5.17 million, pending insurer confirmation. Standalone revenue from operations grew ~30.8% YoY to Rs 1,026.20 million in Q3 and ~24.6% YoY to Rs 3,023.75 million for 9M, but standalone PAT for 9M slipped ~11.6% to Rs 375.78 million and consolidated 9M PAT fell ~16.9% to Rs 363.87 million versus the prior year. The board also approved incorporation of a new subsidiary, Rivadu Lifesciences Private Limited, a pharma/lifesciences venture with at least 70% holding and initial capital up to Rs 25 lakh.
Strong top-line growth is offset by 9M profit decline and a qualified audit opinion tied to an unresolved insurance claim, which adds uncertainty around the carrying value of the fire-damaged assets. The new pharma subsidiary signals diversification beyond speciality chemicals but is very small in initial capital and unlikely to move the needle near-term.